OTC continuous glucose monitors are now mainstream for non-diabetic longevity users. Here's how Abbott Lingo, Dexcom Stelo, and the new entrants compare on accuracy, app quality, cost, and what's actually useful for healthspan.
In 2024, the FDA cleared the first over-the-counter continuous glucose monitors for non-diabetic users — Abbott's Lingo and Dexcom Stelo. By 2026, the market has expanded to include several competitors, dramatically lower prices, and a much richer ecosystem of analytic apps. This guide compares the major options for longevity-focused users and explains what data is actually useful.
Postprandial glucose excursions — spikes after meals — drive several aging-relevant processes: glycation of proteins, oxidative stress, vascular endothelial damage, and chronic insulin demand. People with the same fasting glucose can have dramatically different glucose curves, and most don't know it without measurement.
A two-week CGM trial gives you actionable data: which foods spike your glucose, how exercise blunts spikes, how sleep deprivation worsens insulin sensitivity, and whether your meal timing makes things better or worse. For most users, the right framework is two weeks of intensive learning, then targeted re-measurement rather than continuous lifelong wear.
The original OTC entrant. 14-day sensor worn on the upper arm. Streams to a dedicated Lingo app with a "metabolic score" that emphasizes time-in-range and post-meal stability. Sensor accuracy is excellent (MARD ~9%). The app is the most consumer-friendly of the lot, with food logging and exercise overlays.
Cost: $89 per 14-day sensor; subscription bundles available.